

Figure 3 illustrates the effect of high temperature (65°C) on APC, SL-APC, and XL-APC stability. The graphs illustrates the decrease in % of initial fluorescence or change in relative fluorescence intensity (CPS) (measured at 660 nm) over time when Native APC, SL-APC, and XL-APC when stored at 65°C.

Figure 4 illustrates the emission spectra for GL-APC, when stored in dimethyl sulfoxide at 5 min and 5 days as compared to a control. Additionally, Figure 4 illustrates the emission spectra for XL-APC and SL-APC when stored in dimethyl sulfoxide at 90 min and 5 days as compared to a control.

Figure 5 illustrates the detection of phosphorylated poly-GAT with europium labeled anti-phosphotyrosine IgG (PY20) and SL-APC labeled streptavidin or a commercially available XL-APC labeled streptavidin. Poly-GAT was phosphorylated with a src-tyrosine kinase and then titrated from 0 ng to 12 ng. Positive phosphorylation was measured as a ratio using two wavelengths (620 & 650 nm) as previously described. *See*, Mathis, *Clin. Chem.*, 41:1391-1397, 1995.

Figure 6 illustrates a comparison of two tyrosine kinase inhibitors, staurosporine, and PP-1, on src tyrosine kinase activity measured in a TR-FET assay using SL-APC/Europium chelate as the FRET pair. Figure 7 illustrates the comparison of four europium acceptor dyes (XL-APC, SL-APC, PBXL-3, CryptoFlour-2) for europium chelate emission in a TR-FRET assay titrating the inhibition of β -insulin receptor tyrosine kinase activity with staurosporine (top graph) and 5-iodotubercidin (bottom graph).

REMARKS

Applicants have made several amendments to the specification. In general, the amendments include a description of the figures. The amendments do not entail the introduction of new matter and are supported by the specification and claims as filed. Applicants assert that the specification supports the amendments on page 4 line 23 to page 5 line 12. Similarly, the description of the figures is supported by the description with the originally filed figures 2-7.

CONCLUSION

For the reasons set forth above, it is respectfully submit that Applicants' amended specification should be introduced into the application. If any outstanding issues remain, the examiner is invited to telephone the undersigned at the telephone number indicated below to